Antares Pharma - ATRS Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRS, but not buy additional shares or sell existing shares.
View ATRS analyst ratings or view top-rated stocks.

5 brokers have issued 1-year target prices for Antares Pharma's shares. Their ATRS share price forecasts range from $5.60 to $5.60. On average, they anticipate the company's stock price to reach $5.60 in the next year. This suggests a possible upside of 0.2% from the stock's current price.
View analysts price targets for ATRS or view top-rated stocks among Wall Street analysts.

Antares Pharma's stock was trading at $3.57 on January 1st, 2022. Since then, ATRS stock has increased by 56.6% and is now trading at $5.59.
View the best growth stocks for 2022 here.

Antares Pharma, Inc. (NASDAQ:ATRS) announced its earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to analyst estimates of $48.52 million. Antares Pharma had a trailing twelve-month return on equity of 7.43% and a net margin of 21.90%. During the same quarter in the previous year, the firm posted $0.03 earnings per share.

5 employees have rated Antares Pharma Chief Executive Officer Paul K. Wotton on Glassdoor.com. Paul K. Wotton has an approval rating of 18% among the company's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Antares Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%). Insiders that own company stock include Anton Gueth, Fred M Powell, Leonard S Jacob, Marvin Samson, Peter J Graham, Robert F Apple and Thomas J Garrity.
View institutional ownership trends.

Shares of ATRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRS stock can currently be purchased for approximately $5.59.

Antares Pharma (NASDAQ:ATRS) has a market capitalization of $955.06 million and generates $183.98 million in revenue each year. The specialty pharmaceutical company earns $46.29 million in net income (profit) each year or $0.24 on an earnings per share basis.

The company employs 201 workers across the globe.

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The official website for the company is www.antarespharma.com. The specialty pharmaceutical company can be reached via phone at (609) 359-3020, via email at jhowarth@antarespharma.com, or via fax at 302-655-5049.